Gene Expression Profiling of Early- and Late-Relapse Nonseminomatous Germ Cell Tumor and Primitive Neuroectodermal Tumor of the Testis

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2368-2378

  Sugimura, Jun ^a,b   Foster, Richard S ^c   Cummings, Oscar W ^c   Kort, Eric J ^a   Takahashi, Masayuki ^a,d   Lavery, Todd T ^a   Furge, Kyle A ^a   Einhorn, Lawrence H ^c   Teh, Bin Tean ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b IWATE MEDICAL UNIVERSITY   (Japan)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; EMBRYONAL CARCINOMA; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; NEUROECTODERM TUMOR; NON SEMINOMATOUS GERMINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TESTIS TERATOMA; TESTIS TUMOR; TUMOR GROWTH; TUMOR RECURRENCE; UNINDEXED SEQUENCE; YOLK SAC TUMOR;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TERATOMA; TESTICULAR NEOPLASMS; TIME FACTORS;

EID: 1842426585     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0341     Document Type: Article

References (49)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Silverberg E. Cancer in young adults (ages 15 to 34). CA Cancer J Clin 1982;32:32-42.
3. Mostofi FK, Sobin LH, Sesterhenn IA. Histological typing of testis tumours (International Histological Classification of Tumours). Berlin: Springer-Verlag; 1998.
4. Michael H, Hull MT, Ulbright TM, Foster RS, Miller KD. Primitive neuroectodermal tumors arising in testicular germ cell neoplasms. Am J Surg Pathol 1997;21:896-904.
5. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH. Late relapse of testicular cancer. J Clin Oncol 1995;13:1170-6.
6. Atkin NB, Baker MC. Specific chromosome change, i(12p), in testicular tumours? Lancet 1982;2:1349.
7. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 2001;98:9754-9.
8. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (Lond) 2000;403:503-11.
9. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869-74.
10. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-5.
11. Rodriguez S, Jafer O, Goker H, et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p11.2-p12.1. Oncogene 2003;22:1880-91.
12. Skotheim RI, Monni O, Mousses S, et al. New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res, 2002;62:2359-64.
13. Sobin LH, Wittekind C, editors. International Union Against Cancer. TNM classification of malignant tumours, 5th ed. New York: John Wiley & Sons, 1997.
14. Hegde P, Qi R, Abernathy K, et al. A concise guide to cDNA microarray analysis. Biotechniques 2000;29:548-50, 552-4, 556 passim.
15. Eisen MB, Brown PO. DNA arrays for analysis of gene expression. Methods Enzymol 1999;303:179-205.
16. Cleveland WS. Robust locally weighted regression and smooth-ing scatterplots. J Am Statistic Assoc 1979;74:829-836.
17. Cleveland WS, Devlin SJ. Locally-weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc 1988;83:596-610.
18. Yang YH, Dudoit S, Luu P, et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002;30:e15.
19. Yang YH, Dudoit S, Luu P, Speed TP. Normalization for cDNA microarray data. In: Bittner ML, Chen Y, Dorsel AN, Dougherty ER, editors. Microarrays: optical technologies and informatics. Vol. 4266 of Proceedings of SPIE. Bellingham, WA: The International Society for Optical Engineering; 2001.
20. Ihaka R, Gentleman RR. A language for data analysis and graphics. J Comp Graph Stat 1996;5:299-314.
21. Rhodes DR, Miller JC, Haab BB, Furge KA. CIT: identification of differentially expressed clusters of genes from microarray data. Bioinformatics 2002;18:205-6.
22. Clamp M, Andrews D, Barker D, et al. Ensembl 2002: accommodating comparative genomics. Nucleic Acids Res 2003;31:38-42.
23. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998;95:14863-8.
24. Schwarz M, Wanke I, Wulbrand U, Moennikes O, Buchmann A. Role of connexin32 and β-catenin in tumor promotion in mouse liver. Toxicol Pathol 2003;31:99-102.
25. Chisholm CA, Vavelidis F, Lovell MA, et al. Prenatal diagnosis of multiple acyl-CoA dehydrogenase deficiency: association with elevated α-fetoprotein and cystic renal changes. Prenat Diagn 2001;21:856-9.
26. Nishida K, Tamura A, Nakazawa N, et al. The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 1997;90:526-34.
27. Lin H, Huber R, Schlessinger D, Morin PJ. Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 1999;59:807-10.
28. Xiang YY, Ladeda V, Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001;20:7408-12.
29. Zhu Z, Friess H, Kleeff J, et al. Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer. Am J Surg 2002;184:78-83.
30. Toretsky JA, Zitomersky NL, Eskenazi AE, et al. Glypican-3 expression in Wilms tumor and hepatoblastoma. J Pediatr Hematol Oncol 2001;23:496-9.
31. Zhu ZW, Friess H, Wang L, et al. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut, 2001;48:558-64.
32. Chen L, O'Bryan JP, Smith HS, Liu E. Overexpression of matrix Gla protein mRNA in malignant human breast cells: isolation by differential cDNA hybridization. Oncogene 1990;5:1391-5.
33. Levedakou EN, Strohmeyer TG, Effert PJ, Liu ET. Expression of the matrix Gla protein in urogenital malignancies. Int J Cancer 1992;52:534-7.
34. Hsu YC, Perin MS. Human neuronal pentraxin II (NPTX2): conservation, genomic structure, and chromosomal localization. Genomics 1995;28:220-7.
35. Wilson PO, Barber PC, Hamid QA, et al. The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol 1988;69:91-104.
36. Wang Y, Einhorn P, Triche TJ, Seeger RC, Reynolds CP. Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors. Clin Cancer Res 2000;6:551-8.
37. Izumi H, Takahashi C, Oh J, Noda M. Tissue factor pathway inhibitor-2 suppresses the production of active matrix metalloproteinase-2 and is down-regulated in cells harboring activated ras oncogenes. FEBS Lett 2000;481:31-6.
38. Miyamoto T, Hasuike S. Isolation and expression analysis of the human RNH2 gene encoding ribonuclease inhibitor 2. J Assist Reprod Genet 2002;19:394-7.
39. Talken BL, Lee DR, Caldwell CW, Quinn TP, Schafermeyer KR, Hoffman RW. Analysis of T cell receptors specific for U1-70kD small nuclear ribonucleoprotein autoantigen: the (x chain complementarity determining region three is highly conserved among connective tissue disease patients. Hum Immunol 1999;60:200-8.
40. Hirota K, Matsui M, Murata M, et al. Nucleoredoxin, glutaredoxin, and thioredoxin differentially regulate NF-κB, AP-1, and CREB activation in HEK293 cells. Biochem Biophys Res Commun 2000;274:177-82.
41. Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 2002;4:295-303.
42. Naoe T, Tagawa Y, Kiyoi H, et al. Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy. Leukemia (Baltimore) 2002;16:203-8.
43. Anderer G, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000;10:715-26.
44. Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 2000;95:1222-8.
45. Lear JT, Smith AG, Heagerty AH, et al. Truncal site and detoxifying enzyme polymorphisms significantly reduce time to presentation of further primary cutaneous basal cell carcinoma. Carcinogenesis (Lond) 1997;18:1499-1503.
46. Jiang J, Neubauer BL, Graff JR, et al. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Pathol 2002;160:667-71.
47. Graff JR, Konicek BW, Deddens JA, et al. Expression of group IIa secretory phospholipase A2 increases with prostate tumor grade. Clin Cancer Res 2001;7:3857-61.
48. Yamashita S, Yamashita J, Ogawa M. Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 1994;69:1166-70.
49. Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000;18:3346-51.